| Recruiting | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Othe NCT07129252 | Crinetics Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms NCT06785597 | European Institute of Oncology | — |
| Recruiting | A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens NCT06732505 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Tr NCT06855095 | The Netherlands Cancer Institute | Phase 2 / Phase 3 |
| Recruiting | Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors NCT06276309 | Fujian Maternity and Child Health Hospital | — |
| Recruiting | A Study of PM8002 in Combination With Chemotherapy in Patients With NEN NCT05879055 | Biotheus Inc. | Phase 2 |
| Recruiting | YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. NCT06337760 | European Institute of Oncology | — |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Recruiting | Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) NCT05165407 | Peking University | Phase 2 |
| Unknown | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm NCT05113355 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutet NCT04750954 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients NCT06343428 | European Institute of Oncology | — |
| Unknown | Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis NCT04931446 | Xian-Jun Yu | — |
| Unknown | Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm NCT04927611 | Fudan University | — |
| Unknown | Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONE NCT04720391 | European Institute of Oncology | — |
| Recruiting | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) NCT04464122 | University of Roma La Sapienza | — |
| Active Not Recruiting | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers NCT04459273 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients NCT04917484 | Tine Gregersen, MD | Phase 2 |
| Completed | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) NCT03980925 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Active Not Recruiting | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors NCT03950609 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors NCT03734913 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors NCT03375320 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver NCT03457948 | Nicholas Fidelman, MD | Phase 2 |
| Unknown | A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms NCT03511768 | Xiangya Hospital of Central South University | Phase 1 / Phase 2 |
| Withdrawn | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine NCT02831179 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors NCT03001349 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Unknown | Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging NCT02817945 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Recruiting | Project: Every Child for Younger Patients With Cancer NCT02402244 | Children's Oncology Group | — |
| Completed | Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung NCT02402920 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors NCT02399215 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or L NCT00569127 | National Cancer Institute (NCI) | Phase 3 |